RT Journal Article
SR Electronic
T1 Sequencing SARS-CoV-2 in Slovakia: An Unofficial Genomic Surveillance Report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.13.21260431
DO 10.1101/2021.07.13.21260431
A1 Broňa Brejová
A1 Viktória Hodorová
A1 Kristína Boršová
A1 Viktória Čabanová
A1 Tomáš Szemes
A1 Matej Mišík
A1 Boris Klempa
A1 Jozef Nosek
A1 Tomáš Vinař
YR 2021
UL http://medrxiv.org/content/early/2021/07/18/2021.07.13.21260431.abstract
AB We present an unofficial SARS-CoV-2 genomic surveillance report from Slovakia based on approximately 3500 samples sequenced between March 2020 and May 2021. Early samples show multiple independent imports of SARS-CoV-2 from other countries. In Fall 2020, three virus variants (B.1.160, B.1.1.170, B.1.258) dominated as the number of cases increased. In November 2020, B.1.1.7 (alpha) variant was introduced in Slovakia and quickly became the most prevalent variant in the country (> 75% of new cases by early February 2021 and > 95% in mid-March).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been supported by the Operational Program Integrated Infrastructure project ITMS:313011ATL7 "Pangenomics for personalized clinical management of infected persons based on identified viral genome and human exome" (90&) co-financed by the European Regional Development Fund. The research was also supported by a grant from VEGA 1/0458/18 to TV (10&). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Ethics committee of Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia (Ethics committee statement No. EK/BmV-02/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available through GISAID database. https://gisaid.org